Does Rallies show Form 4 insider transactions for DXR?

Yes. Rallies tracks DXR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DXR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DXR. It does not provide personalized investment advice.

DXR (Daxor Corporation Common Stock) Stock Analysis - Insider Trades

Daxor Corporation Common Stock (DXR) is a publicly traded Healthcare sector company. As of May 21, 2026, DXR trades at $11.35 with a market cap of $63.81M and a P/E ratio of 0.00. DXR moved +0.00% today. Year to date, DXR is -21.38%; over the trailing twelve months it is +50.73%. Its 52-week range spans $6.55 to $14.76. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces DXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DXR stock inside the company?

Recent DXR insider activity includes Feldschuh Michael Richard bought 1.00K, Michel Robert J bought 1.00K, Feldschuh Michael Richard bought 2.06K, Michel Robert J bought 1.00K, and Feldschuh Michael Richard bought 3.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DXR Key Metrics

Key financial metrics for DXR
Metric	Value
Price	$11.35
Market Cap	$63.81M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.03%
52-Week High	$14.76
52-Week Low	$6.55
Volume	0
Avg Volume	0
Revenue (TTM)	$1.45M
Net Income	$-7.19M
Gross Margin	54.89%

Recent DXR Insider Trades

Feldschuh Michael Richard bought 1.00K (~$9.07K) on Apr 8, 2026.
Michel Robert J bought 1.00K (~$9.90K) on Mar 31, 2026.
Feldschuh Michael Richard bought 2.06K (~$16.28K) on Apr 4, 2025.
Michel Robert J bought 1.00K (~$8.00K) on Mar 10, 2025.
Feldschuh Michael Richard bought 3.36K (~$25.80K) on Mar 10, 2025.

Latest DXR News

Daxor Validates BVA’s 20% Hourly Albumin Leak Detection in Heart Failure Study — Mar 26, 2026
Daxor Reports 45% Revenue Growth, NAV Per Share Hits $9.07 After FDA Clearance — Mar 3, 2026
Daxor Launches 98% Accurate BVA Outpatient Program in Tennessee with 24h Turnaround — Feb 24, 2026

DXR Analyst Consensus

2 analysts cover DXR: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.

Common questions about DXR

Who is trading DXR stock inside the company?: Recent DXR insider activity includes Feldschuh Michael Richard bought 1.00K, Michel Robert J bought 1.00K, Feldschuh Michael Richard bought 2.06K, Michel Robert J bought 1.00K, and Feldschuh Michael Richard bought 3.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DXR?: Yes. Rallies tracks DXR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DXR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DXR. It does not provide personalized investment advice.